MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, announced today that its second quarter 2025 financial results will be released after the markets close on Tuesday, August 12th. DiaMedica will host a live conference call on Wednesday, August 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial res
Related Questions
Are there any significant changes in the cash burn rate or runway length after the Q2 results?
Did any of the recent data or trial results suggest de‑risking or increased risk for the upcoming FDA submission?
Did the company provide any updated guidance or outlook for future quarters or the full year?
How does the current valuation compare to peer companies in the same therapeutic space?
How might the Q2 results impact the stock’s short‑term technical momentum and trading volumes?
What is management’s view on the potential commercial market size for the company's lead candidates?
What were the key financial metrics reported for Q2 2025 (revenue, net loss, cash balance, R&D spend)?
Are there any changes in the capital raise plans or upcoming financing activities?
Did the business update reveal any new partnership, licensing, or collaboration agreements?
Was there any discussion of regulatory filings or FDA interaction timelines?
What milestones were achieved in the development programs for preeclampsia and acute ischemic stroke?
What were the notable changes in operating expenses, SG&A, or other cost structures?